CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Changes in Registrant’s Certifying AccountantItem 4.01.Changes in Registrant’s Certifying Accountant.
(a)Dismissal of Independent Registered Public Accounting Firm
On July 12, 2017, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”), dismissed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm. The dismissal of PwC was approved by the audit committee of the board of directors of the Company (the “Audit Committee”).
The reports of PwC on the Company’s financial statements for the fiscal years ended December31, 2016 and December31, 2015 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principle.
During the fiscal years ended December31, 2016 and December31, 2015 and the subsequent interim period through July 12, 2017, there have been no disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference thereto in their reports on the Company’s financial statements.
During the fiscal years ended December 31, 2016 and December 31, 2015 and the subsequent interim period through July 12, 2017, there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K under the Securities Exchange Act of 1934, as amended).
The Company has provided PwC with a copy of the disclosures made herein and has requested that PwC furnish a letter addressed to the U.S. Securities and Exchange Commission stating whether it agrees with the statements made herein. A copy of PwC’s letter is included as Exhibit 16.1 to this Form 8-K.
(b)Appointment of New Independent Registered Public Accounting Firm
On July 12, 2017, the Audit Committee appointed Ernst & Young LLP (“Ernst & Young”) as the Company’s independent registered public accounting firm for the year ending December31, 2017.
During the fiscal years ended December31, 2016 and December31, 2015 and the subsequent interim periods preceding the dismissal of PwC, the Company has not consulted with Ernst & Young regarding either (i)the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report was provided to the Company or oral advice was provided that Ernst & Young concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii)any matter that was the subject of a disagreement (as defined in paragraph (a)(1)(iv) of Item304 of Regulation S-K) or a reportable event (as described in paragraph (a)(1)(v) of Item304 of Regulation S-K).
Item 9.01.Financial Information and Exhibits
Reference is made to the Exhibit Index Attached hereto.
CytomX Therapeutics, Inc. ExhibitEX-16.1 2 ctmx-ex161_15.htm EX-16.1 ctmx-ex161_15.htm EXHIBIT 16.1 July 17,…To view the full exhibit click
About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.